AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells in Vitro and in Vivo

Overview

Journal Cancer Res

Specialty Oncology

Date 2009 Apr 16

PMID 19366807

Citations 44

Authors

Adedayo Oke

Daniel Pearce

Robert W Wilkinson

Claire Crafter

Rajesh Odedra

Jamie Cavenagh

Jude Fitzgibbon

Andrew T Lister

Simon Joel

Dominique Bonnet

Affiliations

Soon will be listed here.

Abstract

Aurora kinases play a critical role in regulating mitosis and cell division, and their overexpression has been implicated in the survival and proliferation of human cancer. In this study, we report the in vitro and in vivo activities of AZD1152, a compound that has selectivity for aurora B kinase, in acute myeloid leukemia (AML) cell lines, primary AML samples, and cord blood cells. AZD1152 exerted antiproliferative or cytotoxic effects in all cell lines studied, inhibited the phosphorylation of histone H3 (pHis H3) on Ser10 in a dose-dependent manner, and resulted in cells with >4N DNA content. THP-1 cells treated with AZD1152 accumulated in a state of polyploidy and showed a senescent response to the drug, in contrast to the apoptotic response seen in other cell lines. Accordingly, AZD1152 profoundly affected the growth of AML cell lines and primary AML in an in vivo xenotransplantation model. However, concentration-dependent effects on cell growth, apoptosis, and cell cycle progression were also observed when human cord blood and primary lineage-negative stem and progenitor cells were analyzed in vitro and in vivo. These data suggest that the inhibition of aurora B kinase may be a useful therapeutic strategy in the treatment of AML and that further exploration of dosing and treatment schedules is warranted in clinical trials.

Citing Articles

AURKB promotes colorectal cancer progression by triggering the phosphorylation of histone H3 at serine 10 to activate CCNE1 expression.

Li L, Xie K, Xie H, Wang L, Li Z, Lu Q Aging (Albany NY). 2024; 16(9):8019-8030.

PMID: 38713155 PMC: 11132018. DOI: 10.18632/aging.205801.

Differential ABC transporter expression during hematopoiesis contributes to neutrophil-biased toxicity of Aurora kinase inhibitors.

Chou D, Furlong B, Posey R, Kyprianou C, OSullivan L, David R Nat Commun. 2022; 13(1):6021.

PMID: 36224199 PMC: 9556712. DOI: 10.1038/s41467-022-33672-4.

Targeting tumor cell senescence and polyploidy as potential therapeutic strategies.

Saleh T, Carpenter V, Bloukh S, Gewirtz D Semin Cancer Biol. 2020; 81:37-47.

PMID: 33358748 PMC: 8214633. DOI: 10.1016/j.semcancer.2020.12.010.

The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?.

Luserna di Rora A, Martinelli G, Simonetti G J Hematol Oncol. 2019; 12(1):123.

PMID: 31771633 PMC: 6880427. DOI: 10.1186/s13045-019-0808-4.

Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.

Payton M, Cheung H, Ninniri M, Marinaccio C, Wayne W, Hanestad K Mol Cancer Ther. 2018; 17(12):2575-2585.

PMID: 30266802 PMC: 6279493. DOI: 10.1158/1535-7163.MCT-18-0186.

References

Girdler F, Gascoigne K, Eyers P, Hartmuth S, Crafter C, Foote K . Validating Aurora B as an anti-cancer drug target. J Cell Sci. 2006; 119(Pt 17):3664-75. DOI: 10.1242/jcs.03145. View

Hogge D, Feuring-Buske M, Gerhard B, Frankel A . The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leuk Res. 2004; 28(11):1221-6. DOI: 10.1016/j.leukres.2004.03.015. View

Adams R, CARMENA M, Earnshaw W . Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol. 2001; 11(2):49-54. DOI: 10.1016/s0962-8924(00)01880-8. View

Ditchfield C, Johnson V, Tighe A, Ellston R, Haworth C, Johnson T . Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol. 2003; 161(2):267-80. PMC: 2172902. DOI: 10.1083/jcb.200208091. View

Harrington E, Bebbington D, Moore J, Rasmussen R, Ajose-Adeogun A, Nakayama T . VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004; 10(3):262-7. DOI: 10.1038/nm1003. View

Guzman M, Rossi R, Karnischky L, Li X, Peterson D, Howard D . The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005; 105(11):4163-9. PMC: 1895029. DOI: 10.1182/blood-2004-10-4135. View

Jung F, Pasquet G, Lambert-van der Brempt C, Lohmann J, Warin N, Renaud F . Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem. 2006; 49(3):955-70. DOI: 10.1021/jm050786h. View

Wilkinson R, Odedra R, Heaton S, Wedge S, Keen N, Crafter C . AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007; 13(12):3682-8. DOI: 10.1158/1078-0432.CCR-06-2979. View

Crosio C, Fimia G, Loury R, Kimura M, Okano Y, Zhou H . Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol. 2002; 22(3):874-85. PMC: 133550. DOI: 10.1128/MCB.22.3.874-885.2002. View

10.

Manfredi M, Ecsedy J, Meetze K, Balani S, Burenkova O, Chen W . Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A. 2007; 104(10):4106-11. PMC: 1820716. DOI: 10.1073/pnas.0608798104. View

11.

Guzman M, Swiderski C, Howard D, Grimes B, Rossi R, Szilvassy S . Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A. 2002; 99(25):16220-5. PMC: 138592. DOI: 10.1073/pnas.252462599. View

12.

Bonnet D, Dick J . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7):730-7. DOI: 10.1038/nm0797-730. View

13.

Tang C, Lin C, Tang T . Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis. Dev Biol. 2006; 290(2):398-410. DOI: 10.1016/j.ydbio.2005.11.036. View

14.

Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y . AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007; 110(6):2034-40. DOI: 10.1182/blood-2007-02-073700. View

15.

Liu X, Yue P, Khuri F, Sun S . Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res. 2005; 65(20):9169-75. DOI: 10.1158/0008-5472.CAN-05-0939. View

16.

Meraldi P, Honda R, Nigg E . Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev. 2004; 14(1):29-36. DOI: 10.1016/j.gde.2003.11.006. View

17.

Katayama H, Sasai K, Kawai H, Yuan Z, Bondaruk J, Suzuki F . Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004; 36(1):55-62. DOI: 10.1038/ng1279. View

18.

Mortlock A, Foote K, Heron N, Jung F, Pasquet G, Lohmann J . Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem. 2007; 50(9):2213-24. DOI: 10.1021/jm061335f. View